Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO4538 in Patients With Rhabdoid Tumor
NCT06622941Phase 2Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2024
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in malignant rhabdoid tumor (MRT), sponsored by Ono Pharmaceutical. Started Nov 2024; status: recruiting.
02
Drugs
03
Conditions
malignant rhabdoid tumor (MRT)
Beyond the preview
Go deeper on NCT06622941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06622941.